Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 in advanced NSCLC
NCT01380769Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jun 2011
- Primary completion
- Feb 2013
- Modality
- Polymer-based Nanoparticles
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing CRLX101 with Best supportive care (2 arms). Primary endpoint: Overall Survival at 18 months. Started Jun 2011; status: completed.
02
Drugs
CRLX101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01380769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380769.